Business Context and Reporting Period
Company: Helix Acquisition Corp. II (Note: The input metadata references "Bridgebio Oncology," but the filing text is for Helix Acquisition Corp. II, a Cayman Islands special purpose acquisition company or SPAC).
Reporting Period: Quarter ended June 30, 2024.
Business Overview: The Company is a blank check company formed to effect a merger, share exchange, or asset acquisition with one or more businesses, focusing on healthcare and healthcare-related industries. As of June 30, 2024, the Company had not commenced operations. Its primary activity is identifying a target for a Business Combination.
Key Event: The Company consummated its Initial Public Offering (IPO) on February 13, 2024, selling 18,400,000 Class A ordinary shares (including full exercise of the over-allotment option) at $10.00 per share, generating gross proceeds of $184,000,000.
Key Financial Metrics
| Metric | Value (Six Months Ended June 30, 2024) | Value (Three Months Ended June 30, 2024) |
|---|---|---|
| Net Income | $3,312,978 | $2,212,536 |
| Operating Expenses | $219,044 (G&A) + $116,772 (Share-based comp) | $152,343 (G&A) + $77,400 (Share-based comp) |
| Interest Income (Trust Account) | $3,648,794 | $2,442,279 |
| Cash and Cash Equivalents | $1,814,499 | $1,814,499 |
| Marketable Securities in Trust Account | $187,648,794 | $187,648,794 |
| Total Assets | $189,874,488 | $189,874,488 |
| Total Liabilities | $5,599,141 | $5,599,141 |
| Deferred Underwriting Fee | $5,520,000 | $5,520,000 |
| Net Cash Used in Operating Activities | ($647,098) | N/A |
Material Changes vs. Prior Period
- Revenue and Operations: The Company had no operating revenue or operations for the three and six months ended June 30, 2023. The current period reflects the post-IPO status with significant interest income generated from the Trust Account.
- Net Income: Net income increased from $0 in the prior year periods to $3.31 million for the six months ended June 30, 2024, driven entirely by interest earned on marketable securities held in the Trust Account.
- Balance Sheet: Total assets increased from $332,894 at December 31, 2023, to $189.9 million at June 30, 2024, primarily due to the $184 million placed in the Trust Account following the February 2024 IPO.
- Share Capital: Class A ordinary shares subject to possible redemption increased from 0 to 18,400,000 shares. Class B ordinary shares (Founder Shares) were adjusted via share capitalization to 4,600,000 shares.
Outlook, Risks, and Management Commentary
- Business Combination Deadline: The Company has 24 months from the closing of the IPO (February 13, 2024) to complete an initial Business Combination. If not completed, the Company will liquidate and redeem Public Shares.
- Liquidity: The Company holds $1.81 million in cash outside the Trust Account for working capital and transaction costs. It intends to use Trust Account funds (including interest) to complete a Business Combination. The Sponsor may provide working capital loans if necessary.
- Redemption Rights: Public shareholders have the right to redeem their shares for a pro-rata share of the Trust Account upon the completion of a Business Combination or liquidation.
- Risks: The Company is an emerging growth company and a shell company. Risks include the inability to complete a Business Combination within the required timeframe, potential dilution, and the possibility that the per-share redemption value may be less than $10.00 if the Trust Account value declines (though currently protected by interest income).
- Deferred Fees: A deferred underwriting fee of $5,520,000 is payable only upon the successful completion of a Business Combination.
Investor Verification Checklist
- Trust Account Balance: Verify the current balance of $187.65 million and the composition of assets (U.S. Treasury bills) to ensure liquidity for potential redemptions.
- Extension Options: Confirm the specific terms and shareholder approval requirements for extending the 24-month deadline to complete a Business Combination.
- Related Party Transactions: Review the administrative services agreement ($6,458/month) and the potential for working capital loans from the Sponsor.
- Redemption Thresholds: Understand the conditions under which shareholders can redeem shares and the impact of mass redemptions on the Company's ability to close a deal.
- Deferred Underwriting Fee: Note the $5.52 million liability that will only be settled if a Business Combination is consummated.